Sinovac Biotech Ltd. (NASDAQ: SVA) received notification that it has regained compliance with Nasdaq Global Market listing requirements, the Beijing-based biopharmaceutical company announced.

The company received a letter dated June 10, 2026, from a Nasdaq hearing advisor stating that Sinovac now complies with Listing Rule 5250(c)(1) and meets all listing requirements. The notification followed the company's filing of its annual report on Form 20-F for the year ended December 31, 2025, which was submitted on June 5, 2026.

A scheduled hearing before the Nasdaq Hearings Panel has been canceled as a result of the compliance restoration. However, Sinovac remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027, as determined by the Hearing Panel on May 20, 2026.

The company specializes in research, development, manufacturing and commercialization of vaccines for human infectious diseases. Its portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease, poliomyelitis, and pneumococcal disease.

Three of Sinovac's vaccines have received World Health Organization prequalification: the inactivated hepatitis A vaccine Healive, Sabin-strain inactivated polio vaccine, and varicella vaccine. The company also developed CoronaVac, an inactivated COVID-19 vaccine.